american society of anesthesiologists glp-1 Consensus-Based Guidance on Preoperative Management of Patients on Glucagon-Like Peptide-1 EUGENOL | ASA - American

The Australia GLP-1 receptor agonist market size was valued at USD 570.49 million in 2025 and is expected to hit around USD 2,117.46 million by 2035, growing at a CAGR of 14.01% from 2026 to 2035.

These headwinds have led to a sharp decline in its stock price, raising questions about the long-term impact of its gamble.

Abstract The development oftirzepatide, a first in class dual glucose dependent insulinotropic polypeptide andglucagon like peptide 1 receptor agonist, represents a potentially transformative advance in the management oftype 2 diabetesandobesity

Summary GLP-1 RAs alter gastrointestinal motility at all levels of the GI tract, with delayed gastric emptying being the most well characterized

GLP-1 drugs are reshaping healthcare and consumer markets

Perfect For